There are some things in life you want to be consistent and predictable. Interest rates. Train timetables. The weather. And if you work in the pharma industry, the FDA.

However, like leaves on the line or unexpected hail storms, there are factors in the regulatory environment that mean it is not always so easy to anticipate. Taking a new drug or medical device to market is a long, unpredictable process at the best of times, but clearing that final hurdle of regulatory approval remains a real challenge. 

In this eBook we explore key issues in the current regulatory environment, including the impact of Covid on drug green lights and a potential end-of-year boost to drug approvals.

Please fill in the form to access your complimentary copy of Pharma Market Drivers: Blowin’ in the Wind.    



How Covid failed to derail the FDA
Is biopharma getting better at accelerated approval conversions?
Novartis has the most new approvals, but Lilly’s are worth more
Will we see a late flurry of FDA approvals?